logo-loader

Faron explores options for drug ingredients manufacturing

Published: 21:16 02 Oct 2019 AEST

Faron Pharmaceuticals Ltd - Faron explores options for drug ingredients manufacturing
German producer Rentschler Biopharma issued contract termination notice

Faron Pharmaceuticals Ltd (LON:FARN) is exploring options for ingredients manufacturing of Traumakine, its lead drug candidate.

The drug company received a contract termination notice from German producer Rentschler Biopharma, which was providing the active pharmaceutical ingredient (API) manufacturing.

READ: Faron Pharma in talks to find partner for lead cancer drug

The decision was related to the “significant” upgrade to the manufacturing process that would be required to receive approval by the European and US authorities to produce the drug.

Faron said this termination has no impact on the ongoing clinical advice process, as it focuses on a clinical study structure for Traumakine, which is used to treat acute respiratory distress.

Studies in the development of Traumakine revealed it requires a design to avoid administering in combination with corticosteroids, which Faron has already submitted for feedback.

Once the design is approved, the AIM-listed firm will carry on discussions for third party funding, as announced last week.

Shares were down 2.79% to 97.7p at noon.

 

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18